80 phenotypes from 6 alleles in 7 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Pitx3ak/Pitx3ak either: (involves: 129/Sv * C57BLKS) or (involves: 129/Sv * C57BL/6)	abnormal anterior eye segment morphology	J:5084
	abnormal eye distance/ position	J:5084
	abnormal iris pigmentation	J:5084
	abnormal lens development	J:5084
	abnormal midbrain morphology	J:82746, J:82907
	abnormal ocular fundus morphology	J:5084
	abnormal posterior eye segment morphology	J:5084
	abnormal retina morphology	J:5084
	acoria	J:5084
	decreased body size	J:5084
	decreased locomotor activity	J:82907
	decreased substantia nigra size	J:82746
	enlarged lacrimal gland	J:5084
	microphthalmia	J:5084
	reduced fertility	J:5084
	retina fold	J:5084
Pitx3ak/Pitx3ak involves: 129S1/Sv * C57BL/6 * C57BLKS/J	abnormal dorsal striatum morphology	J:109319
	abnormal locomotor behavior	J:98209
	abnormal substantia nigra pars compacta morphology	J:109319
	decreased dopamine level	J:109319
	decreased vertical activity	J:98209
	impaired coordination	J:98209
	increased locomotor activity	J:98209
	loss of dopaminergic neurons	J:109319
Pitx3eyl/Pitx3eyl involves: C3H/He * C57BL/6	abnormal food intake	J:156878
	abnormal immunoglobulin level	J:156878
	abnormal respiration	J:156878
	abnormal respiratory function	J:156878
	abnormal retina morphology	J:156878
	aphakia	J:156878
	decreased anxiety-related response	J:156878
	decreased blood uric acid level	J:156878
	decreased body length	J:156878
	decreased body weight	J:156878
	decreased bone mass	J:156878
	decreased chemical nociceptive threshold	J:156878
	decreased circulating amylase level	J:156878
	decreased circulating cholesterol level	J:156878
	decreased circulating iron level	J:156878
	decreased circulating triglyceride level	J:156878
	decreased dopaminergic neuron number	J:156878
	decreased exploration in new environment	J:156878
	decreased grip strength	J:156878
	decreased IgG3 level	J:156878
	decreased IgM level	J:156878
	decreased leukocyte cell number	J:156878
	decreased thermal nociceptive threshold	J:156878
	decreased tidal volume	J:156878
	decreased total body fat amount	J:156878
	disorganized retina layers	J:156878
	eyelids fail to open	J:156878
	fused cornea and lens	J:156878
	hepatic steatosis	J:156878
	hyperresponsive to tactile stimuli	J:156878
	increased anxiety-related response	J:156878
	increased blood uric acid level	J:156878
	increased body temperature	J:156878
	increased CD4-positive, alpha-beta T cell number	J:156878
	increased CD8-positive, alpha-beta T cell number	J:156878
	increased circulating alkaline phosphatase level	J:156878
	increased circulating phosphate level	J:156878
	increased cornea thickness	J:156878
	increased energy expenditure	J:156878
	increased granulocyte number	J:156878
	increased lean body mass	J:156878
	increased pulmonary respiratory rate	J:156878
	microphthalmia	J:156878
	retina fold	J:156878
	thrombocytopenia	J:156878
Pitx3tm1.1(KOMP)Vlcg/Pitx3tm1.1(KOMP)Vlcg C57BL/6N-Pitx3tm1.1(KOMP)Vlcg/J	abnormal motor coordination/balance	J:211773
	abnormal motor learning	J:211773
	abnormal sleep behavior	J:211773
	anophthalmia	J:211773
	decreased vertical activity	J:211773
	hyperactivity	J:211773
	increased coping response	J:211773
	increased fasting circulating glucose level	J:211773
	increased grip strength	J:211773
	increased heart rate	J:211773
	shortened ST segment	J:211773
Pitx3tm1.1Jdr/Pitx3tm1.1Jdr involves: 129 * 129X1/SvJ * C57BL/6	abnormal eye morphology	J:122955
	loss of dopaminergic neurons	J:122955
Pitx3tm1Mli/Pitx3tm1Mli involves: 129P2/OlaHsd	increased neuron apoptosis	J:99395
	increased neuron number	J:99395
	loss of dopaminergic neurons	J:99395
Pitx3tm2Mli/Pitx3tm2Mli Not Specified	normal nervous system phenotype	J:133341